Shea M, Hmiel S P, Beck A M
Division of Pediatric Nephrology, Washington University School of Medicine, and St. Louis Children's Hospital, St. Louis, Missouri, USA.
Adv Perit Dial. 2001;17:249-52.
Peritoneal dialysis is often the renal replacement therapy of choice in pediatric patients, but the smaller catheters are at high risk for occlusion by fibrin clots. Tissue-type plasminogen activator (t-PA) is a recombinant protease specific for fibrin, and has been shown to be an effective thrombolytic for central venous catheters. The present study aimed to demonstrate the effectiveness of t-PA for thrombolysis in occluded peritoneal catheters. Six patients between 3 weeks and 15 years of age presented with 7 episodes of occluded peritoneal catheters. In all cases, t-PA (2 mg in 40 mL normal saline) was instilled into the catheter. Patency was assessed after 60 minutes by rapid instillation and drainage of 10 mL dialysis solution per kilogram patient body weight. Thrombolysis was effective in 4 of 7 attempts. In 2 cases, occlusion occurred in the setting of acute peritonitis. In 2 cases, catheters required surgical replacement. One child developed a leak at the catheter exit site within 24 hours after treatment. No intraperitoneal bleeding was observed, and no changes were observed in systemic coagulation indices [prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen degradation products (FDP), and fibrinogen] assessed pre- and post-thrombolysis. In cases of occluded PD catheters, t-PA appears to be an effective and safe treatment.
腹膜透析通常是儿科患者首选的肾脏替代疗法,但较小的导管有被纤维蛋白凝块阻塞的高风险。组织型纤溶酶原激活剂(t-PA)是一种对纤维蛋白具有特异性的重组蛋白酶,已被证明是一种治疗中心静脉导管血栓形成的有效溶栓剂。本研究旨在证明t-PA对阻塞性腹膜导管溶栓的有效性。6例年龄在3周至15岁之间的患者出现了7次腹膜导管阻塞。在所有病例中,将t-PA(2mg溶于40mL生理盐水中)注入导管。60分钟后,通过以每千克患者体重快速注入和引流10mL透析液来评估通畅情况。7次尝试中有4次溶栓有效。2例患者在急性腹膜炎时发生阻塞。2例患者的导管需要手术更换。1名儿童在治疗后24小时内导管出口处出现渗漏。未观察到腹腔内出血,溶栓前后评估的全身凝血指标[凝血酶原时间(PT)、活化部分凝血活酶时间(aPTT)、纤维蛋白原降解产物(FDP)和纤维蛋白原]也未观察到变化。对于阻塞性腹膜透析导管病例,t-PA似乎是一种有效且安全的治疗方法。